

ZydaClin™
(clindamycin)

Oral Drops

liquid

For Use in Dogs & Cats

Equivalent to 25 mg per mL clindamycin

Not for use in humans

Keep out of reach of children

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

ANADA 200-538, Approved by FDA

DESCRIPTION

ZydaClin™ Oral Drops contain clindamycin hydrochloride which is the hydrate salt of clindamycin. Clindamycin is a semisynthetic antibiotic produced by a 7(S)-chlorosubstitution of the 7(R)-hydroxyl group of a naturally produced antibiotic produced by *Streptomyces lincolnensis* var. *lincolnensis*.

ZydaClin™ Oral Drops (For Use in Dogs and Cats) is a palatable formulation intended for oral administration. Each mL of ZydaClin™ Oral Drops liquid contains clindamycin hydrochloride equivalent to 25 mg clindamycin; and ethyl alcohol, 8.64%.

ACTION

Site and Mode of Action: Clindamycin is an inhibitor of protein synthesis in the bacterial cell. The site of binding appears to be in the 50S sub-unit of the ribosome. Binding occurs to the soluble RNA fraction of certain ribosomes, thereby inhibiting the binding of amino acids to those ribosomes. Clindamycin differs from cell wall inhibitors in that it causes irreversible modification of the protein-synthesizing subcellular elements at the ribosomal level.

MICROBIOLOGY

Clindamycin is a lincosaminide antimicrobial agent with activity against the wide variety of aerobic and anaerobic bacterial pathogens. Clindamycin is a bacteriostatic compound that inhibits bacterial protein synthesis by binding to 50S ribosomal sub-unit. The minimum inhibitor concentrations (MICs) of Gram-positive and obligate anaerobic pathogens isolated from dogs and cats in the United States are presented in the Table 1 and Table 2. Bacteria were isolated in 1998-1999. All MICs were performed in accordance with the National committee for Clinical Standards (NCCLS).

Table 1. Clindamycin MIC Values ($\mu\text{g/mL}$) from Diagnostic Laboratory Survey Data Evaluating Canine Pathogens in the U.S. during 1998-99¹

Organism	Number of isolates	MIC ₅₀	MIC ₉₀	MIC ₁₀₀	Range
Soft Tissue/Wound²					
<i>Staphylococcus aureus</i>	17	0.5	0.5	≥ 4.0	0.25- ≥ 4.0
<i>Staphylococcus intermedius</i>	28	0.25	0.5	≥ 4.0	0.125- ≥ 4.0
<i>Staphylococcus</i> spp.	18	0.5	0.5	≥ 4.0	0.25- ≥ 4.0
Beta-hemolytic streptococci	46	0.5	0.5	≥ 4.0	0.25- ≥ 4.0
<i>Streptococcus</i> spp.	11	0.5	≥ 4.0	≥ 4.0	0.25- ≥ 4.0
Osteomyelitis/Bone³					
<i>Staphylococcus aureus</i>	20	0.5	0.5	0.5	0.5 ⁴
<i>Staphylococcus intermedius</i>	15	0.5	≥ 4.0	≥ 4.0	0.25- ≥ 4.0
<i>Staphylococcus</i> spp.	18	0.5	≥ 4.0	≥ 4.0	0.25- ≥ 4.0
Beta-hemolytic streptococci	21	0.5	2.0	2.0	0.25- ≥ 4.0
<i>Streptococcus</i> spp.	21	≥ 4.0	≥ 4.0	≥ 4.0	0.25- ≥ 4.0
Dermal/Skin⁵					
<i>Staphylococcus aureus</i>	25	0.5	≥ 4.0	≥ 4.0	0.25- ≥ 4.0
<i>Staphylococcus intermedius</i>	48	0.5	≥ 4.0	≥ 4.0	0.125- ≥ 4.0
<i>Staphylococcus</i> spp.	32	0.5	≥ 4.0	≥ 4.0	0.25- ≥ 4.0
Beta-hemolytic streptococci	17	0.5	0.5	0.5	0.25-0.5

¹ The correlation between the *in vitro* susceptibility data and clinical response has not been determined.

² Soft Tissue/Wound: includes samples labeled wound, abscess, aspirate, exudates, draining tract, lesion, and mass.

³ Osteomyelitis/Bone: includes samples labeled bone, fracture, joint, tendon.

⁴ No range, all isolates yielded the same value.

⁵ Dermal/Skin: includes samples labeled skin, skin swab, biopsy, incision, lip.

Table 2. Clindamycin MIC Values ($\mu\text{g/mL}$) from Diagnostic Laboratory Survey Data Evaluating Feline Pathogens from Wound and Abscess Samples in the U.S. during 1998¹

Organism	Number of isolates	MIC ₅₀	MIC ₉₀	Range
<i>Bacteroides/Prevotella</i>	30	0.06	4.0	≤ 0.015 -4.0
<i>Fusobacterium</i> spp.	17	0.25	0.25	≤ 0.015 -0.5
<i>Peptostreptococcus</i> spp.	18	0.13	0.5	≤ 0.015 -8.0
<i>Porphyromonas</i> spp.	13	0.06	0.25	≤ 0.015 -8.0


¹ The correlation between the *in vitro* susceptibility data and clinical response has not been determined.

PHARMACOLOGY

Absorption: Clindamycin hydrochloride is rapidly absorbed from the canine and feline gastrointestinal tract.


Dog Serum Levels:

Serum levels at or above 0.5 µg/mL can be maintained by oral dosing at a rate of 2.5 mg/lb of clindamycin hydrochloride every 12 hours. This same study revealed that average peak serum concentrations of clindamycin occur 1 hour and 15 minutes after oral dosing. The elimination half-life for clindamycin in dog serum was approximately 5 hours. There was no bioactivity accumulation after a regimen of multiple oral doses in healthy dogs.



Cat Serum Levels:

Serum levels at or above 0.5 µg/mL can be maintained by oral dosing at a rate of 5 mg/lb of clindamycin hydrochloride liquid every 24 hours. The average peak serum concentration of clindamycin occurs approximately 1 hour after oral dosing. The elimination half-life of clindamycin in feline serum is approximately 7.5 hours. In healthy cats, minimal accumulation occurs after multiple oral doses of clindamycin hydrochloride, and steady-state should be achieved by the third dose.



METABOLISM AND EXCRETION

Extensive studies of the metabolism and excretion of clindamycin hydrochloride administered orally in animals and humans have shown that unchanged drug and bioactive and bioinactive metabolites are excreted in urine and feces. Almost all of the bioactivity detected in serum after clindamycin hydrochloride product administration is due to the parent molecule (clindamycin). Urine bioactivity, however, reflects a mixture of clindamycin and active metabolites, especially N-dimethyl clindamycin and clindamycin sulfoxide.

ANIMAL SAFETY SUMMARY

Rat and Dog Data: One year Oral toxicity studies in rats and dogs at doses of 30, 100 and 300 mg/kg/day (13.6, 45.5 and 136.4 mg/lb/day) have shown clindamycin hydrochloride to be well tolerated. Differences did not occur in the parameters evaluated to assess toxicity when comparing groups of treated animals with contemporary controls. Rats administered clindamycin hydrochloride at 600 mg/kg/day (272.7 mg/lb/day) for six months tolerated the drug well; however, dogs orally dosed at 600 mg/kg/day (272.7 mg/lb/day) vomited, had anorexia and subsequently lost weight. At necropsy these dogs had erosive gastritis and focal areas of necrosis of the mucosa of the gall bladder.

Safety in gestating bitches or breeding males has not been established.

Cat Data: The recommended daily therapeutic dose range for Clindamycin Hydrochloride Oral Liquid is 11 to 33 mg/kg/day (5 to 15 mg/lb/day) depending on the severity of the condition. Clindamycin hydrochloride liquid was tolerated with little evidence of toxicity in domestic shorthair cats when administered orally at 10 X the minimum recommended therapeutic daily dose (11 mg/kg 5 mg/lb) for 15 days, and at doses up to 5 X the minimum recommended therapeutic dose for 42 days. Gastrointestinal tract upset (soft feces to diarrhea) occurred in control and treated cats with emesis occurring at doses 3 X or greater than the minimum recommended therapeutic dose (11 mg/kg/day; 5 mg/lb/day). Lymphocytic inflammation of the gallbladder was noted in a greater number of treated cats at the 110 mg/kg/day (50 mg/lb/day) dose level than control cats. No other effects were noted. Safety in gestating queens or breeding male cats has not been established.

INDICATIONS

ZydaClin™ Oral Drops (for use in dogs and cats) are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below:

Dogs: Skin infections (wounds and abscesses) due to coagulase positive staphylococci (*Staphylococcus aureus* or *Staphylococcus intermedius*). **Deep wounds and abscesses** due to *Bacteroides fragilis*, *Prevotella melaninogenicus*, *Fusobacterium necrophorum* and *Clostridium perfringens*.

Dental infections due to *Staphylococcus aureus*, *Bacteroides fragilis*, *Prevotella melaninogenicus*, *Fusobacterium necrophorum* and *Clostridium perfringens*. **Osteomyelitis** due to *Staphylococcus aureus*, *Bacteroides fragilis*, *Prevotella melaninogenicus*, *Fusobacterium necrophorum* and *Clostridium perfringens*.

Cats: Skin infections (wounds and abscesses) due to *Staphylococcus aureus*, *Staphylococcus intermedius*, *Streptococcus spp.* **Deep wounds and abscesses** due to *Clostridium perfringens* and *Bacteroides fragilis*.

Dental infections due to *Staphylococcus aureus*, *Staphylococcus intermedius*, *Streptococcus spp.*, *Clostridium perfringens* and *Bacteroides fragilis*.

CONTRAINDICATIONS

ZydaClin™ Oral Drops are contraindicated in animals with a history of hypersensitivity to preparations containing clindamycin or lincomycin.

Because of potential adverse gastrointestinal effects, do not administer to rabbits, hamsters, guinea pigs, horses, chinchillas or ruminating animals

HUMAN WARNINGS

Keep out of reach of children. Not for human use.

PRECAUTIONS

During prolonged therapy of one month or greater, periodic liver and kidney function tests and blood counts should be performed.

The use of ZydaClin™ Oral Drops occasionally results in overgrowth of non-susceptible organisms such as clostridia and yeasts. Therefore, the administration of ZydaClin™ Oral Drops should be avoided in those species sensitive to the gastrointestinal effects of clindamycin (see **CONTRAINDICATIONS**). Should superinfections occur, appropriate measures should be taken as indicated by the clinical situation.

Patients with very severe renal disease and/or very severe hepatic disease accompanied by severe metabolic aberrations should be dosed with caution, and serum clindamycin levels monitored during high dose therapy.

Clindamycin hydrochloride has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore, ZydaClin™ Oral Drops should be used with caution in animals receiving such agents.

Safety in gestating bitches and queens or breeding male dogs and cats has not been established.

ADVERSE REACTIONS

Side effects occasionally observed in either clinical trials or during clinical use were vomiting and diarrhea.

To report a suspected adverse reaction or to request a Safety Data Sheet (MSDS) call 1-800-524-6332.

DOSAGE AND ADMINISTRATION

Dogs:

Infected Wounds, Abscesses and Dental Infections

Oral: 2.5-15.0 mg/lb body weight every 12 hours.

Duration: Treatment with ZydaClin™ Oral Drops may be continued up to a maximum of 28 days if clinical judgment indicates. Treatment of acute infections should not be continued for more than three or four days if no response to therapy is seen.

Dosage Schedule:

ZydaClin™ Oral Drops, administer 1-6 mL/10 lb body weight every 12 hours.

Dogs:

Osteomyelitis

Oral: 5.0-15.0 mg/lb body weight every 12 hours.

Duration: Treatment with ZydaClin™ Oral Drops is recommended for a minimum of 28 days. Treatment should not be continued for longer the 28 days if no response to therapy is seen.

Dosage Schedule:

ZydaClin™ Oral Drops, administer 2-6 mL/10 lb body weight every 12 hours.

Cats:

Infected Wounds, Abscesses and Dental Infections

Oral: 5.0-15.0 mg/lb body weight every 24 hours depending on the severity of the condition.

Duration: Treatment with ZydaClin™ Oral Drops may be continued up to a maximum for a minimum of 14 days if clinical judgment indicates. Treatment of acute infections should not be continued for more than three to four days if no clinical response to therapy is seen.

Dosage Schedule:

ZydaClin™ Oral Drops, to provide 5.0 mg/lb administer 1 mL/5 lb body weight once every 24 hours; to provide 15.0 mg/lb administer 3 mL/5 lb body weight once every 24 hours.

HOW SUPPLIED

ZydaClin™ Oral Drops is available as 20mL filled in 30 mL bottles (25 mg/mL) supplied in packers containing 12 cartoned bottles with direction labels and calibrated dosing droppers.

To report a suspected adverse reaction or to request a Safety Data Sheet (MSDS) call 1-800-524-6332.

Store at controlled room temperature 20°-25°C (68°-77°F) [see USP].

20 mL
VET one
ZydaClin™
(clindamycin)
Oral Drops liquid

NDC 13985-555-25

20 mL

DIRECTIONS: _____

VET one
ZydaClin™
(clindamycin)
Oral Drops

VET one
ZydaClin™
(clindamycin)
Oral Drops
liquid

VET one
ZydaClin™
(clindamycin)
Oral Drops

EACH mL CONTAINS: Clindamycin hydrochloride equivalent to 25 mg clindamycin; and ethyl alcohol, 8.64%.

RECOMMENDED DOG DOSAGE: For therapy of wounds, abscesses and dental infections, orally administer 2.5 - 15.0 mg/lb (1 - 6 mL/10 lbs) body weight every 12 hours.

For therapy of osteomyelitis orally administer 5.0 - 15.0 mg/lb (2-6 mL/10 lbs) body weight every 12 hours.

RECOMMENDED CAT DOSAGE: For therapy of wounds, abscesses and dental infections, orally administer 1 - 3 mL/5 lbs body weight once every 24 hours depending on the severity of the condition.

See package insert for complete product information.

Store at 20°C to 25°C (68°F - 77°F) [see USP]

THIS CARTON CONTAINS:
20 mL of ZydaClin™ Oral Drops liquid in a 30 mL bottle.

TAKE TIME
OBSERVE LABEL DIRECTIONS

For use in Dogs & Cats
Equivalent to 25 mg per mL clindamycin

Not for use in humans
Keep out of reach of children

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

ANADA 200-538,
Approved by FDA

V1 510143

Net Contents: 20mL

MADE IN USA

Distributed by: MWI
Boise, ID 83705
(888) 694-8381
www.VetOne.net

Manufactured by: Bimeda, Inc.
18 Street, MN 55056
Product No: 1CL006
SCL005 Rev. 06/13

3 13985 01054 5



FOR USE IN DOGS AND CATS

ANIMAL SAFETY SUMMARY

Rat and Dog Data:

One year oral toxicity studies in rats and dogs at doses of 30, 100 and 300 mg/kg/day (13.6, 45.5 and 136.4 mg/lb/day) have shown clindamycin hydrochloride capsules to be well tolerated.

Cat Data: The recommended daily therapeutic dose range for clindamycin hydrochloride (ZydaClin™ Oral Drops) is 11 to 33 mg/kg/day (5 to 15 mg/lb/day) depending on the severity of the condition.

Patients with very severe renal disease and/or very severe hepatic disease accompanied by severe metabolic aberrations should be dosed with caution, and serum clindamycin levels monitored during high-dose therapy.

INDICATIONS

ZydaClin™ Oral Drops (for use in dogs and cats) are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below.

Dogs: Skin infections (wounds and abscesses) due to coagulase positive staphylococci (Staphylococcus aureus or Staphylococcus intermedius). Deep wounds and abscesses due to Bacteroides fragilis, Prevotella melanogigicus, Fusobacterium necrophorum and Clostridium perfringens.

Dental infections due to Staphylococcus aureus, Bacteroides fragilis, Prevotella melanogigicus, Fusobacterium necrophorum and Clostridium perfringens. Otitis media due to Staphylococcus aureus, Bacteroides fragilis, Prevotella melanogigicus, Fusobacterium necrophorum and Clostridium perfringens.

Cats: Skin infections (wounds and abscesses) due to Staphylococcus aureus, Staphylococcus intermedius, Streptococcus spp. Deep wounds and abscesses due to Clostridium perfringens and Bacteroides fragilis.

Dental infections due to Staphylococcus aureus, Staphylococcus intermedius, Streptococcus spp., Clostridium perfringens and Bacteroides fragilis.

CONTRAINDICATIONS

ZydaClin™ Oral Drops are contraindicated in animals with a history of hypersensitivity to preparations containing clindamycin or lincomycin.

Because of potential adverse gastrointestinal effects, do not administer to rabbits, hamsters, guinea pigs, horses, chinchillas or ruminating animals.

HUMAN WARNINGS

Keep out of reach of children. Not for use in humans.

PRECAUTIONS

During prolonged therapy of one month or greater, periodic liver and kidney function tests and blood counts should be performed.

The use of ZydaClin™ Oral Drops occasionally results in overgrowth of non-susceptible organisms such as clostridia and yeasts. Therefore, the administration of ZydaClin™ Oral Drops should be avoided in those species sensitive to the gastrointestinal effects of clindamycin (see CONTRAINDICATIONS). Should superinfections occur, appropriate measures should be taken as indicated by the clinical situation.



FOR USE IN DOGS AND CATS

Patients with very severe renal disease and/or very severe hepatic disease accompanied by severe metabolic aberrations should be dosed with caution, and serum clindamycin levels monitored during high-dose therapy.

Clindamycin hydrochloride has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore, ZydaClin™ Oral Drops should be used with caution in animals receiving such agents.

Safety in gestating bitches and queens or breeding male dogs and cats has not been established.

ADVERSE REACTIONS

Side effects occasionally observed in either clinical trials or during clinical use were vomiting and diarrhea.

To report adverse reactions or a suspected adverse reaction call 1-888-524-6332.

DOSAGE AND ADMINISTRATION

Dogs: Infected Wounds, Abscesses, and Dental Infections

Dose: 2.5-15.0 mg/lb body weight every 12 hours.

Duration: Treatment with ZydaClin™ Oral Drops may be continued up to a maximum of 28 days if clinical judgment indicates. Treatment of acute infections should not be continued for more than three or four days if no response to therapy is seen.

DOSAGE SCHEDULE: ZydaClin™ Oral Drops, administer 1-6 mL/10 lbs body weight every 12 hours.

Dogs: Osteomyelitis

Dose: 5.0-15.0 mg/lb body weight every 12 hours.

Duration: Treatment with ZydaClin™ Oral Drops is recommended for a minimum of 28 days. Treatment should not be continued for longer than 28 days if no response to therapy is seen.



FOR USE IN DOGS AND CATS

DOSAGE SCHEDULE: ZydaClin™ Oral Drops, administer 2-6 mL/10 lbs body weight every 12 hours.

Cats:

Infected Wounds, Abscesses, and Dental Infections

Dose: 5.0 - 15.0 mg/lb body weight once every 24 hours depending on the severity of the condition.

Duration: Treatment with ZydaClin™ Oral Drops may be continued up to a maximum of 14 days if clinical judgment indicates. Treatment of acute infections should not be continued for more than three to four days if no clinical response to therapy is seen.

Dosage Schedule: ZydaClin™ Oral Drops, to provide 5.0 mg/lb, administer 1 mL/5 lbs body weight once every 24 hours; to provide 15.0 mg/lb, administer 3 mL/5 lbs body weight once every 24 hours.

HOW SUPPLIED

ZydaClin™ Oral Drops is available as 20 mL, filled in 30 mL bottles (25 mg/mL) applied in packages containing 12 calibrated bottles with direction labels and calibrated dosing droppers.

To report a suspected adverse reaction or to request a material safety data sheet (MSDS), call 1-888-524-6332.

Store at 20°C - 25°C (68°F - 77°F) [see USP].



Distributed by: MWI
Boise, ID 83705
(888) 694-8381
www.VetOne.net

Manufactured by: Bimeda, Inc.
St. Louis, MO 63108

80L003
Rev. 06/13



FOR USE IN DOGS AND CATS



FOR USE IN DOGS AND CATS



FOR USE IN DOGS AND CATS



FOR USE IN DOGS AND CATS



FOR USE IN DOGS AND CATS

ANADA 200-538, Approved by FDA

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION

ZydaClin™ Oral Drops contain clindamycin hydrochloride which is the hydrated salt of clindamycin. Clindamycin is a semisynthetic antibiotic produced by a 7(S)-chlorosubstitution of the 7(S)-hydroxyl group of a naturally produced antibiotic produced by Streptomyces clostridioferus var. lincolnensis.

ZydaClin™ Oral Drops (For Use in Dogs and Cats) is a palatable formulation intended for oral administration. Each mL of ZydaClin™ Oral Drops liquid contains clindamycin hydrochloride equivalent to 25 mg clindamycin; and ethyl alcohol, 9.64%.

ACTIONS

Site and Mode of Action: Clindamycin is an inhibitor of protein synthesis in the bacterial cell. The site of binding appears to be in the 50S sub-unit of the ribosome. Binding occurs to the soluble RNA fraction of certain ribosomes, thereby inhibiting the binding of amino acids to those ribosomes. Clindamycin differs from oral wall inhibitors in that it causes irreversible modification of the protein-synthesizing subunit elements at the ribosomal level.

MICROBIOLOGY

Clindamycin is a lincosamide antimicrobial agent with activity against a wide variety of aerobic and anaerobic bacterial pathogens. Clindamycin is a bacteriostatic compound that inhibits bacterial protein synthesis by binding to the 50S ribosomal sub-unit. The minimum inhibitory concentrations (MIC) of Gram-positive and obligate anaerobic pathogens isolated from dogs and cats in the United States are presented in Table 1 and Table 2. Bacteria were isolated in 1998-1999. All MICs were performed in accordance with the National Committee for Clinical Laboratory Standards (NCCLS).

Table 1. Clindamycin MIC Values (µg/mL) from Diagnostic Laboratory Survey Data Evaluating Canine Pathogens in the U.S. during 1998-99

Table with 5 columns: Organism, Number of Isolates, MIC50, MIC90, Range. Rows include Staphylococcus aureus, Staphylococcus intermedius, Beta-hemolytic streptococci, Streptococcus spp., Clostridium/Bacteroides, Staphylococcus aureus, Staphylococcus intermedius, Staphylococcus spp., Beta-hemolytic streptococci, Staphylococcus aureus, Staphylococcus intermedius, Staphylococcus spp., Beta-hemolytic streptococci.

*The correlation between the in vitro susceptibility data and clinical response has not been determined.
†Soft tissue/abscess includes sample labeled wound, abscess, sprain, nodule, draining tract, lesion, and mass.
‡Osteomyelitis/Bone includes sample labeled bone, fracture, joint, lesion.
§No range, all isolates yielded the same value.
¶Dermal/Skin includes sample labeled skin, skin/teeth, biopsy, infection, etc.

Table 2. Clindamycin MIC Values (µg/mL) from Diagnostic Laboratory Survey Data Evaluating Feline Pathogens from Wound and Abscess Samples in the U.S. during 1998

Table with 5 columns: Organism, Number of Isolates, MIC50, MIC90, Range. Rows include Bacteroides/Prevotella, Fusobacterium spp., Pasteurella, Porythomonas spp.


†The correlation between the in vitro susceptibility data and clinical response has not been determined.

PHARMACOLOGY

Absorption: Clindamycin hydrochloride is rapidly absorbed from the canine and feline gastrointestinal tract.

Dog Serum Levels:


Serum levels at or above 0.5 µg/mL can be maintained by oral dosing at a rate of 2.5 mg/lb of clindamycin hydrochloride every 12 hours. This same study revealed that average peak serum concentrations of clindamycin occur 1 hour and 15 minutes after oral dosing. The elimination half-life for clindamycin in dog serum was approximately 5 hours. There was no bioactivity accumulation after a regimen of multiple oral doses in healthy dogs.



Cat Serum Levels:

Serum levels at or above 0.5 µg/mL can be maintained by oral dosing at a rate of 5 mg/lb of clindamycin hydrochloride liquid every 24 hours. The average peak serum concentration of clindamycin occurs approximately 1 hour after oral dosing. The elimination half-life of clindamycin in feline serum is approximately 7.5 hours. In healthy cats, minimal accumulation occurs after multiple oral doses of clindamycin hydrochloride and steady-state should be achieved by the third dose.

Clindamycin Serum Concentrations 5 mg/lb (11 mg/kg) After Single Oral Dose of Clindamycin Hydrochloride Liquid to Cats



METABOLISM AND EXCRETION

Extensive studies of the metabolism and excretion of clindamycin hydrochloride administered orally in animals and humans have shown that unchanged drug and bioactive and inactive metabolites are excreted in urine and feces. Almost all of the bioactivity detected in serum after clindamycin hydrochloride product administration is due to the parent molecule (clindamycin). Urine bioactivity, however, reflects a mixture of clindamycin and active metabolites, especially N-desmethyl clindamycin and clindamycin sulfide.

ZYDACLIN

clindamycin solution/ drops

Product Information

Product Type	PRESCRIPTION ANIMAL DRUG	Item Code (Source)	NDC:13985-555
Route of Administration	ORAL		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
CLINDAMYCIN HYDROCHLORIDE (UNII: T20OQ1YN1W) (CLINDAMYCIN - UNII:3U02EL437C)	CLINDAMYCIN	25 g in 1 mL

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:13985-555-25	20 mL in 1 BOTTLE		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANADA	ANADA200538	07/25/2013	

Labeler - MWI (019926120)**Registrant** - Bimeda Inc., Division of Cross Vetpharm Group (060492923)**Establishment**

Name	Address	ID/FEI	Business Operations
Bimeda Inc., Division of Cross Vetpharm Group		060492923	manufacture

Revised: 12/2017

MWI